per-prescription of branded (Cipro) ciprofloxacin was $149.34. The sharp decrease in the proportion of brand had come to be "explained by the withdrawal from the market in 2001 because of risk of liver failure. CONCLUSIONS: Increased expenditures for fluoroquinolones paralleled with increased utilization. Generic drug utilization increased dramatically after brand-name patent expiration. Fluoroquinolone drug usage was also associated with its safety profile and related disease treatment guidelines.

PSSA1
ASSOCIATION OF OBESITY WITH 30-DAY READMISSION RATES AMONG PATIENTS HOSPITALIZED WITH ACUTE BACTERIAL SKIN AND SKIN-STRUCTURE INFECTIONS (ABSSSI)
Agyarega R1, Ravi C1, Tang WC1, Faust F1, Tuttle KG2

1Analysis Group Inc., Boston, MA, USA, 2Analysis Group, Inc., New York, NY, USA

OBJECTIVES: Obese patients associated with increased risk of soft tissue infection and clinical failure; however, the association between obesity and longer-term clinical outcomes in ABSSSI patients is not well-studied. This study compared hospital readmission rates between obese and non-obese ABSSSI patients. METHODS: Adults (>18 years) hospitalized with 1 primary ABSSSI diagnosis were selected from the Cerner Healthfacts electronic medical records database (2009-2013). The first primary ABSSSI inpatient admission was defined as the index admission. Patients were stratified by hospital readmission status (≥30) and non-obese cohorts at the index admission. Proportions of patients with all-cause and ABSSSI-related readmission to the same hospital within 30 days were compared between the cohorts descriptively (in subgroups defined by gender, age, and causative pathogens) and using multivariable logistic regression adjusting for hospital size, demographics, insurance type, causative pathogen, and important comorbidities. RESULTS: 5,823 obese and 5,882 non-obese patients were identified. Fewer obese patients were male (47.8% vs. 55.8% of 65 years old (26.2% vs. 33.4%), and admitted to teaching hospitals (70.7% vs. 73.4%). Same-hospital 30-day readmission rates were higher for obese patients for both all-cause (12.9% vs. 11.8%, p < 0.008) and ABSSSI-related (5.3% vs. 4.0% p < 0.0019) readmission. Multivariable logistic regression and diversion readmission rates remained significantly higher for obese patients among males (5.1% vs. 3.8%, p < 0.008), younger patients (age <65 years, 5.0% vs. 6.6%, p = 0.0026), and those not infected with methicillin-resistant staphylococcus aureus (5.3% vs. 4.2%, p = 0.049). In multivariable regressions, obese patients had higher odds of all-cause readmission for all-cause readmissions (obese vs. non-obese: OR = 1.10, p = 0.094) and significantly higher odds of ABSSSI-related readmissions (OR = 1.28, p = 0.0073). CONCLUSIONS: Obese ABSSSI patients experienced higher rates of same-hospital ABSSSI-related readmission compared with non-obese patients. The association persisted in male, age <65, and non-MRSA subgroups and remained significant after adjustment for confounding. Further studies are warranted to estimate total readmission rates, which may be underestimated by same-hospital readmission rates.

PSSA2
BIBLIOGRAPHIC ANALYSIS OF THE WORLDWIDE SCIENTIFIC PRODUCTION OF ORAL HEALTH
Simbaqueba E, Zarama P, Robles A, Upegui A

OBJECTIVES: Identify and analyze the level of scientific production in the oral health field worldwide, by assessing quantitative assessment counting methods and bibliometric analysis. METHODS: The review was realized using the Scopus database, including the quantitative and qualitative data. The literature review was performed using the ‘Citation Analysis Tool’. The results were analyzed through production, dissemination, collaboration and bibliometric indicators, which considered the trends in publication, authors, document type, workspace, magazines, country, number of citations, impact factors, h-index, and references. A descriptive analysis was performed from the public policy context in oral health, in addition to the estimation of trends and state of the art investigation. RESULTS: 1 727 scientific articles were found through searching terms associated with “oral health” AND “public health” AND “public policy”. The annual growth function provided an increased trend since 2000. The United States, Brazil and the United Kingdom were the countries with the highest impact and development in the oral health field, providing 40.7% of the total references found. The production is allied especially to universities and research groups, mainly the University of Sao Paulo, University of Adelaide and University of North Carolina at Chapel Hill. The areas of knowledge with the greater incidence were: medicine (44.1%), Dentistry (35%) and social sciences (4.8%). The search for oral health had an index h: 46. CONCLUSIONS: The scientific production in oral health topics shows increasing development and institutional influence. It is expected that the oral health problems analyzed would have solutions and support from the government of the region and the allocation of resources for health.

PSSA3
BIOLOGIC ADHERENCE AMONG PSORIASIS PATIENTS IN THE US MEDICARE POPULATION
Doshi JA1, Takteja J2, Pinto L2, Li P1, Yu X1, Rao PM1, Vishwanathan HR2, Gelfand JM2
1University of Pennsylvania, Philadelphia, PA, USA, 2Amgen, Thousand Oaks, CA, USA

OBJECTIVES: Biologics have provided major advances in the treatment of plaque psoriasis. Little is known regarding adherence to biologics and factors associated with adherence in the Medicare population. This study is the first to examine adherence among Medicare patients with psoriasis receiving biologics. METHODS: The 2009 to 2012 Medicare 100% files were used to identify patients who received infliximab, ustekinumab, adalimumab, or etanercept between 1/1/2010 and 12/31/2011. The date of first biologic prescription defined the index date. Patients were required to have fee-for-service Medicare Parts A, B, and stand-alone Part D plan coverage in the 12-month pre- and post-index period. Overall, 617 > 1 claim for psoriasis (ICD-SCM code 696.1) in the 12-month pre-index period. Exclusion criteria included presence of other conditions for which these biologics are indicated, or receipt of any biologic in the 12-months pre-index. Adherence to index biologic was defined as patients with proportion of days covered (PDC) > 0.80 during the 12-months post-index. Logistic regression analyses were conducted to determine the factors associated with being adherent. RESULTS: Our sample included 2,707 patients newly initiating biologics. Overall, mean PDC for any index biologic was 0.61 and only 38% were adherent to their index biologic in the 12 months following initiation. Mean PDC and adherence rates were similar between physician-administered and self-administered agents, but there were several differences by index biologic. Mean PDCs were 0.66 for infliximab, 0.61 for ustekinumab (N = 1,181), 0.70 for etanercept (N = 289), 0.63 for adalimumab (N = 1,084), and 0.56 for etanercept (N = 1,025). Adherence rates were 49%, 43%, 41%, and 29%, respectively. Logistic regression indicated that older age, and female gender were associated with poorer adherence to index biologic, while being associated with being adherent. CONCLUSIONS: Adherence with biologic treatment for psoriasis is poor in the Medicare population with rates <50% across all biologics.

URINARY/KIDNEY DISORDERS – Clinical Outcomes Studies

PUEK
COMPARATIVE EFFICACY OF INTERVENTIONS FOR OVERACTIVE BLADDER SYNDROME: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Doshi JA, Dicko DG, Bujkiewicz S, Abrams K
1University of Leicester, Leicester, UK

OBJECTIVES: There is a plethora of interventions for the treatment of overactive bladder syndrome (OAB), which can be categorized into behavioral therapy, anticholinergic medication, sacral nerve stimulation, and more recently, botulinum toxin type A (BoNT-A) and beta-3-adrenergic agonists. Though these interventions provide symptom relief, there is little information about which of them is the most clinically effective. This is largely because trials often compare interventions with a placebo or with interventions of the same class; and so there are a limited number of trials that compare interventions of different classes. METHODS: We searched Medline, EMBASE, Cochrane Incontinence Group Specialized Register, and all relevant references for randomized controlled trials evaluating interventions for OAB through to October 2014. Using Bayesian Markov Chain Monte Carlo (MCMC) methods, we applied a hierarchical network meta-analysis that accounts for the exchangeability of treatment effects between different modes of administration (e.g. extended and immediate release), between treatments within the same class, and the anticholinergic residual bacterial synergy. We further adjusted for differences in baseline severity of the patient population, as different interventions are used at varying times in the treatment pathway. The primary outcomes of interest were change from baseline for urgency, urgency, and incontinence episodes. RESULTS: Preliminary results show that for reducing urgency and episodes, BoNT-A 200u was the most effective intervention. BoNT-A 300u was the most effective intervention for reducing incontinence episodes. CONCLUSIONS: BoNT-A 200u was the most effective intervention for reducing symptoms of OAB. Accounting for the exchangeability between different modes of administration and treatments within in the same class sufficiently increases the precision in the treatment effect estimates but maintains the interpretability of the individual and diverse range of treatment options.

URINARY/KIDNEY DISORDERS – Cost Studies

PUEK
THE BUDGET IMPACT OF TREATMENT PATHWAY REDESIGN IN MEN WITH LOWER URINARY TRACT SYMPTOMS (LUTS) ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA (BPH)
Patel S1, Garnham AF, Niazi P2
1Astellas UK, Chertsey, UK, 2Astellas Pharma EMEA, Chertsey, UK

OBJECTIVES: LUTS associated with BPH (LUTS/BPH) in men may present as a combination of voiding, storage and post-micturition symptoms. UK prescribers have proposed two areas of improvement to current care: first, acknowledging that α-blocker monotherapy may not address bothersome storage symptoms; and second, building confidence in primary care to prescribe drug combinations for mixed symptoms. We built a model to evaluate the potential budget savings from implementing these treatment pathway changes. METHODS: A model was built in Microsoft® Excel to depict a simplified LUTS care pathway, aligned with current clinical practice and NICE treatment recommendations in a hypothetical cohort of 10,000 men with LUTS/BPH who have moderate-to-severe storage and voiding symptoms. The budget impact of a proposed pathway redesign was calculated, which could adjust the number of men diagnosed and managed in primary care. Men would receive a range of treatments based on the modelled efficacy estimates and be prioritized for treatment. Varying degrees of drug use and patient characteristics were varied in a sensitivity analysis. RESULTS: The model estimated several annual cost savings: ~£2,964,169 by increasing the proportion of men diagnosed and treated with α-blocker monotherapy from 6% to 20%. A combinatorial index biologic pathway resulted in a saving of ~£8,208,061. Varying drug combination or cost were shown to have minimal financial impact. CONCLUSIONS: The pathway redesign indicates substantial savings. Specifically, increasing primary care diagnosis and treatment of LUTS/BPH symptoms would avoid referral costs and potentially delay surgery, while increasing general practitioner confidence.
in prescribing multiple drug classes may improve care for men with substan-
tial storage symptoms that have not been adequately addressed by α-blocker
monotherapy.

PUK8 EVALUATING THE ECONOMIC IMPLICATIONS OF NONADHERENCE AND ANTIBODY-MEDIATED REJECTION IN RENAL TRANSPLANT RECIPIENTS: THE ROLE OF ONCE-DAILY, PROLONGED-RELEASE TACROLIMUS IN THE UK SETTING

G.1, Odemuyiwa1, Pollock R2
1Antillas Pharma EMEA, Chertsey, UK; 2Ossian Health Economics and Communications GmbH, Basel, Switzerland

OBJECTIVES: While short-term kidney graft survival has gradually improved over time, improvements in long-term graft survival have been more modest. One key
clinical factor limiting improved long-term outcomes is antibody-mediated rejec-
tion (AbMR). Recent data suggest that AbMR incidence is higher in non-adherent
patients and that this may be improved by reducing pill burden.

The aim of the present study was to model the incidence and economic consequences of graft loss and AbMR with once-daily, prolonged-release (PR) tacrolimus versus twice-daily, immediate-release (IR) tacrolimus in the UK setting. METHODS: A combined de-
cision tree and Markov model was developed to estimate the incidence of graft loss
and AbMR and mortality in renal transplant recipients taking PR versus IR tacrol-
imus. Underlying rates of graft failure and mortality were derived from UK-specific
sources. Proportions of patients adherent to once- and twice-daily tacrolimus
were taken from a recent randomized trial. Relative risks of graft failure and AbMR were
taken from a separate prospective analysis of 315 patients. Cost data were obtained
from the British National Formulary and NHS reference costs and reported in 2014
pounds sterling. RESULTS: Switching patients from IR to PR tacrolimus would result
in projected cost savings of GBP 4,862 per patient over five years, translat-
ing to savings of GBP 486,200 in a hypothetical 100-patient cohort. Mean absolute
per-patient costs with PR tacrolimus were projected to be GBP 40,974 versus GBP
45,836 with IR, with the largest saving arising from reduced dialysis costs, fol-
lowed by reduced pharmacy and AbMR treatment costs. CONCLUSIONS: Modeling
analyses suggest that when compared to IR tacrolimus, PR once-daily, twice-
daily transplants were associated with lower pharmacy, dialysis and AbMR treatment
costs, with the reduction in AbMR and dialysis costs being driven by improved
adherence to PR tacrolimus and the consequent reductions in graft loss and onset
of AbMR.

PUK9 COST OF ILLNESS ANALYSIS OF CHRONIC KIDNEY DISEASE IN THE ENTIRE POPULATION OF THE RUSSIAN FEDERATION

T.E. Klepinin1, K.A. Ionina1,2, A. Kulikov2,3,4
1Research Institute of Urology and Nephrology, Russian Academy of Medical Sciences, Moscow, Russia; 2Inferential, Paris, France

OBJECTIVES: To conduct the “cost of illness” analysis of chronic kidney disease (CKD)
based on the entire population of the Russian Federation. METHODS: Information sources were in the public domain. Pharmacoeconomic analysis method “cost
of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of CKD is not available now. The results of the research showed that the
cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of CKD is not available now. The results of the research showed that the
cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS:
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation
the cost of illness” was used. Direct and indirect cost analysis was also performed. RESULTS: